E0501 1-year clinical outcomes after implantation of sirolimus-eluting stents in patients with coronary artery disease and type 2 diabetes. (17th November 2010)

• Record Type: Journal Article
• Authors: Hongya, Han; Yujie, Zhou; Hanying, Ma; Yuyang, Liu; Dongmei, Shi; Yingxin, Zhao; Xiaoli, Liu; Fei, Gao; Hua, Shen
• Is Part Of: Heart. Volume 96(2010)Supplement 3
• Page Start: 156
• Page End: 156
• Publication Date: 2010-11-17
• Subjects: Heart -- Diseases -- Treatment -- Periodicals; Cardiology -- Periodicals; 616.12
• DOI: 10.1136/hrt.2010.208967.501
• Languages: English
• ISSNs: 1355-6037

Abstract

Abstract : Background: Drug-eluting stents (DES) have been shown to significantly reduce clinical events and angiographic restenosis in the treatment of coronary artery disease (CAD). We aimed to assess the long-term efficacy and safety of two Sirolimus-Eluting Stents (the biodegradable polymer-coated sirolimus-eluting stents, EXCEL and the polymer-based sirolimus-eluting cobalt-chromium stents, Firebird 2) in the treatment of patients with CAD and Type 2 Diabetes. Methods: A total of 320 consecutive patients with coronary artery disease and type 2 diabetes undergoing percutaneous coronary intervention randomised into two groups (EXCEL group, n=158; Firebird 2 group, n=162). Baseline clinical characteristics, procedural success rate and occurrence of major adverse cardiac events (MACE, a composite of death, myocardial infarction or target lesion revascularisation) during follow-up were recorded and compared between the two groups. Results: During hospitalisation no patient had complications. At 1 year follow-up, both of the EXCEL group and Firebird 2 group had lower occurrence of cardiac events (1.9% in the Excel group and 1.2% in the Firebird group, p>0.05). Conclusion: Implantation of EXCEL stent or Firebird 2 stent for patients with coronary artery disease and type 2 diabetes is safe and can reduce major adverse cardiac events in long-term follow-up.